ADLARITY® consistently delivers
donepezil over 7 days1,2
Innovative once-weekly transdermal system with proprietary
Corplex technology1,3
Less than 1 mm thin3,4
Thinner than the average skin thickness of the
human back and/or thigh
Flexibly conforms to
skin movement2,3
Contains a stretch-fabric backing with perforated
layers beneath that enables flexibility
Delivers donepezil consistently2,3
Donepezil is continuously converted in the drug
matrix for consistent delivery through the skin
Adhesion when bathing
or showering2
Even at temperatures up to 108 °F
Cross-sectional view of ADLARITY1
Not to scale. For illustrative purposes only.
Cross-sectional view of ADLARITY1
Not to scale. For illustrative purposes only.
Less than 1 mm thin3,4
Thinner than the average skin thickness of the
human back and/or thigh
Flexibly conforms to
skin movement2,3
Contains a stretch-fabric backing with perforated
layers beneath that enables flexibility
Delivers donepezil consistently2,3
Donepezil is continuously converted in the drug
matrix for consistent delivery through the skin
Adhesion when bathing
or showering2
Even at temperatures up to 108 °F
Transdermal delivery bypasses the GI tract and avoids first-pass hepatic metabolism2,a
Adhesion is maintained throughout the weekly wear period2
First-pass effect occurs when a drug gets metabolized at a specific location in the body (eg, the liver) and results in a reduced concentration of the active drug upon reaching its site of function or systemic circulation.5
In a Phase 1 study that evaluated the steady-state pharmacokinetics of ADLARITY 5 mg/d
and 10 mg/d compared with oral donepezil 10 mg in healthy volunteers2
Continuous delivery reduced fluctuations, resulting in a smoother plasma drug level at steady state2
Mean plasma donepezil concentration-time data after weekly application of ADLARITY
and daily administration of oral donepezil during Week 5 in healthy volunteers2
- ADLARITY 10 mg/d (n=53)b
- ADLARITY 5 mg/d (n=56)b
- Oral donepezil 10 mg/d (n=53)c
Once-weekly ADLARITY demonstrated similar
overall drug exposure
to oral donepezil.2
Applied weekly for a 7-day wear; removed in the morning on Day 36, with donepezil concentration measured on Days 29 to 36.2
Taken once daily for 35 days, with donepezil concentration measured on Days 35 to 36 (no dosing on Day 36). Data shown during Hours 0 to 144 represent a projection of measurements taken on Day 35.2
Designed for adhesion over 7 days1
The ADLARITY transdermal system has demonstrated adhesion throughout the weekly (168-hour) wear period1
Percentage of transdermal systems exhibiting ≥80% surface area adhesion on the back at all time points evaluated (every 12 hours) throughout the 7-day wear period in a study of healthy volunteers1,d
None of the transdermal systems fully detached during the study.1
The adhesion of ADLARITY 5 mg/d was evaluated over 168 hours for 1 week, and the adhesion of ADLARITY 10 mg/d was evaluated over 168 hours for 4 consecutive weeks.1
In a separate study assessing wear at different application sites (back, thigh, and buttock; N=66)1,2,e
- ≥85% of the transdermal systems applied at every site exhibited ≥80% surface area adhesion for the duration of wear (168 hours)1
- 1 full detachment on the back was noted in the study1
The adhesion of ADLARITY 5 mg/d was evaluated over 168 hours for 1 week, and the adhesion of ADLARITY 10 mg/d was evaluated over 168 hours for 4 consecutive weeks.1
183 total transdermal systems were applied (60 on the back, 61 on the thigh, and 62 on the buttock).2
GI, gastrointestinal.
